ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1244

Extracellular MicroRNAs in Synovial Fluid Reveal a Marked Proliferative Signature in Patients with Antibiotic-Refractory Lyme Arthritis

Robert B. Lochhead, Nancy D. Kim, Sheila Arvikar, Klemen Strle and Allen C. Steere, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Arthritis, biomarkers and rheumatoid arthritis (RA), Lyme disease, MicroRNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Lyme arthritis (LA), caused by a tick-borne spirochete Borrelia burgdorferi, usually resolves appropriately with antibiotic treatment, called antibiotic-responsive LA. However, in some patients, arthritis persists for months or years after spirochetal killing with oral and IV antibiotic therapy, called antibiotic-refractory LA. Synovial lesions in these patients show marked synovial proliferation, inflammation, and vascularization, accompanied by pathogenic autoimmunity. MicroRNAs (miRs) regulate many biological processes including inflammation, immune responses, and cell proliferation, and are effective biomarkers that may reveal molecular mechanisms of disease. Our objective here was to identify extracellular miRs (ex-miRs) in synovial fluid (SF) that distinguish regulated (responsive) from dysregulated (refractory) immune responses in LA, thereby providing insights into underlying biological processes and potential diagnostic biomarkers to distinguish between  these disease courses.

Methods:

Using an unbiased systems approach, SF was screened for the expression of 372 ex-miRs commonly found in biofluids, using qPCR, in patients with responsive LA (n=6) or refractory LA (n=5), and for comparison, in those with rheumatoid arthritis (RA, n=4) or osteoarthritis (OA, n=4). A cluster analysis algorithm (Qiagen) was used to identify ex-miR signatures present in one or more patient groups. Statistically significant differences in miR expression between groups were determined by ANOVA (p<0.05).

Results:

In SF from patients with responsive or refractory LA or RA, miRs reflective of an inflammatory signature (miR-146a, miR-155) and a vascularization signature (miR-30fam) were significantly up-regulated compared with that of OA patients. Furthermore, up-regulation of the inflammatory ex-miR signature was more pronounced (~4-6-fold higher) in patients with refractory LA than in those with responsive LA, consistent with the greater expression of inflammatory cytokines in SF of refractory patients. However, the most novel finding in refractory LA was marked up-regulation of a cell proliferation signature, which included miR-223, miR-142, and miR-17-92fam, miRs associated with oncogenesis. For miR-223 and miR-142, two of the most abundant ex-miRs, the amounts were ~3-to-6-fold greater in refractory LA compared with that in responsive LA and OA, and similar to the levels observed in RA SF. Preliminary cell culture experiments suggest that some of these ex-miRs are transferred to fibroblast-like synoviocytes where they alter target gene expression.

Conclusion:

Cell proliferation ex-miR signatures were a key component that distinguished antibiotic-refractory LA or RA from antibiotic-responsive LA or OA. Thus, in antibiotic-responsive LA, a localized inflammatory response to B. burgdorferi infection is down-regulated appropriately, whereas in antibiotic-refractory LA, the greater inflammatory response in joints appears to activate marked synovial proliferation that persists after spirochetal killing. It will be important to determine whether miR-223 and miR-142 may be used as biomarkers to identify patients at risk for a refractory disease course.


Disclosure: R. B. Lochhead, NIAMS (T32 AR007258-36A1), 2; N. D. Kim, None; S. Arvikar, Rheumatology Research Foundation, 2; K. Strle, NIH K (K01AR062098), 2,Arthritis Foundation, 2; A. C. Steere, NIAID (AI-101175), 2,Rolland Foundation, 2,Littauer Foundation, 2,Eshe Fund, 2.

To cite this abstract in AMA style:

Lochhead RB, Kim ND, Arvikar S, Strle K, Steere AC. Extracellular MicroRNAs in Synovial Fluid Reveal a Marked Proliferative Signature in Patients with Antibiotic-Refractory Lyme Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/extracellular-micrornas-in-synovial-fluid-reveal-a-marked-proliferative-signature-in-patients-with-antibiotic-refractory-lyme-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extracellular-micrornas-in-synovial-fluid-reveal-a-marked-proliferative-signature-in-patients-with-antibiotic-refractory-lyme-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology